SCM
HBIO icon

Signia Capital Management’s Harvard Bioscience HBIO Stock Holding History

Signia Capital Management’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-9,284
Closed -$440K – 75
2014
Q1 		$440K Hold
9,284
– – 0.16% 66
2013
Q4 		$436K Buy
9,284
+1,476
+19% +$64.5K 0.16% 68
2013
Q3 		$311K Hold
7,808
– – 0.1% 74
2013
Q2 		$278K Buy
+7,808
New +$299K 0.08% 75

Other funds holding HBIO

GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $18.8B AUM 29.2% 1-Year Est. Return
HSA
Hussman Strategic Advisors Ellicott City, Maryland $463M AUM 16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Signia Capital Management's HBIO Position: Q2 2014 in Review

Signia Capital Management sold out of Harvard Bioscience (HBIO) in Q2 2014, closing a stake of 9,284 shares — an estimated $440K sold.

Signia Capital Management first reported a position in HBIO in Q2 2013 and held it in 4 quarters. The position peaked at $440K in Q1 2014. 74 funds tracked by Wall St. Rank hold HBIO as of Q2 2014.

  • Signia Capital Management reported no remaining Harvard Bioscience position as of Q2 2014 after selling out during the quarter.
  • Signia Capital Management sold 9,284 Harvard Bioscience shares in Q2 2014, an estimated $440K.
  • Signia Capital Management first reported a position in Harvard Bioscience in Q2 2013 and held it in 4 quarters.
  • Signia Capital Management's Harvard Bioscience position peaked at $440K in Q1 2014.
  • 74 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2014.

Based on Signia Capital Management's 13F filing for Q2 2014, filed 13 Aug 2014.